Psychopharmacology in the schools

Psychology in the Schools

Volumn 43, Issue 4, 2006, Pages 493-501

  Abrams, Laura ^a   Flood, Jillian ^a   Phelps, LeAdelle ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33645979383     PISSN: 00333085     EISSN: 15206807     Source Type: Journal    
DOI: 10.1002/pits.20163     Document Type: Article

References (35)

1. American Academy of Child and Adolescent Psychiatry. (2004). 2004N-0330 - Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Pediatric Advisory Committee. Retrieved January 15, 2005, from http://www.aacap.org/Announcements/AACAP_Comment.htm
2. Birmaher, B., Axelson, D., Monk, K., Kalas, C., Clark, D.B., & Ehmann, M. (2003). Fluoxetine for the treatment of childhood anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 415-423.
3. Braconnier, A., Le Coent, R., & Cohen, D. (2003). Paroxetine versus clomipramine in adolescents with severe major depression: A double-blind, randomized, multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 22-29.
4. Brent, D. A. (2004). Treating depression in children: Antidepressants and pediatric depression - The risk of doing nothing. New England Journal of Medicine, 351, 1598-1601.
5. Buitelaar, J.K., Danckaerts, M., Gillberg, C., Zuddas, A., Becker, K., Bouvard, M., et al. (2004). A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. European Child and Adolescent Psychiatry, 13, 249-257.
6. Compton, S.N., Burns, B.J., Egger, H.L., & Robertson, E. (2002). Review of the evidence base for treatment of childhood psychopathology: Internalizing disorders. Journal of Consulting and Clinical Psychology, 70, 1240-1266.
7. Emslie, G.J., Heiligenstein, J.H., Wagner, K.D., Hoog, S.L., Ernest, D.E., & Brown, E. (2002). Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized, clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1205-1215.
8. Food and Drug Administration Center for Drug Evaluation and Research. (2004). Summary minutes of the CDER psychopharmacologic drugs advisory committee and the FDA pediatric advisory committee. Retrieved January 15, 2005, from http://www.fda.gov/ohrms/dockets/ac/04/minutes/2004-4065M1_Final.htm
9. Graae, F., Milner, J., Rizzotto, L., & Klein, R. (1994). Clonazepam in childhood anxiety disorders. Journal of American Academy of Child and Adolescent Psychiatry, 35, 372-377.
10. Guevara, J., Lozano, P., Wickizer, T., Mell, L., & Gephart, H. (2002). Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder. Pediatrics, 109, 733-739.
11. Hall, A.S., & Gushee, A.G. (2002). Medication interventions for ADHD youth: A primer for school and mental health counselors. Journal of Mental Health Counseling, 24, 140-153.
12. Keller, M.B., Ryan, N.D., Strober, M., Klein, R.G., Kutcher, S.P., & Birmaher, B. (2001). Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 762-772.
13. Kratochvil, C.J., Heiligenstein, J.H., Dittmann, R., Spencer, T.J., Biederman, J., Wernicke, J., et al. (2002). Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 776-784.
14. Kutcher, S., Reiter, S., Gardner, D., & Klein, R. (1992). The pharmacotherapy of anxiety disorders in children and adolescents. Psychiatric Clinics of North America, 15, 41-67.
15. March, J.S., Biederman, J., Wolkow, R., Safferman, A., Mardekian, J., Cook, E.H., et al. (1998). Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter controlled trial. Journal of the American Medical Association, 280, 1752-1756.
16. Michelson, D., Allen, A.J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., et al. (2002). Once daily atomoxetine treatment for children and adolescents with ADHD: A randomized, placebo-controlled study. American Journal of Psychiatry, 159, 1896-1901.
17. Michelson, D., Buitelaar, J.K., Danckaerts, M., Gilberg, S., Spencer, T.J., Zuddas, A., et al. (2004). Relapse prevention in pediatric patients with ADHD treated with atomoxetine: A randomized, double-blind, placebo-controlled study. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 806-904.
18. Palumbo, D., Spencer, T., Lynch, J., Co-Chien, H., & Faraone, S.V. (2004). Emergence of tics in children with ADHD: Impact of once-daily OROS methylphenidate therapy. Journal of Child & Adolescent Psychopharmacology, 14, 185-194.
19. Pelham, W.E., Hoza, B., Pillow, D.R., Gnagy, E.M., Kipp, H.L., & Greiner, W.R. (2002). Effects of methylphenidate and expectancy on children with ADHD: Behavior, academic performance and attributions in a summer treatment program and regular classroom settings. Journal of Consulting and Clinical Psychology, 70, 320-335.
20. Phelps, L., Brown, R.T., & Power, T.J. (2002). Pediatric psychopharmacology: Combining medical and psychosocial interventions. Washington, DC: American Psychological Association.
21. Pliszka, S.R. (2003). Non-stimulant treatment of attention-deficit/hyperactivity disorder. CNS Spectrums, 8, 253-258.
22. Research Unit on Pediatric Psychopharmacology Anxiety Study Group. (2001). Fluvoxamine for the treatment of anxiety disorders in children and adolescents. New England Journal of Medicine, 344, 1279-1285.
23. Research Unit on Pediatric Psychopharmacology Anxiety Study Group. (2002). Treatment of pediatric anxiety disorders: An open-label extension of the research units on pediatric psychopharmacology anxiety study. Journal of Child & Adolescent Psychopharmacology, 12, 175-188.
24. Rynn, M.A., Siqueland, L., & Rickels, K. (2001). Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. American Journal of Psychiatry, 158, 2008-2014.
25. Sallee, F., Hilial, R., Dougherty, D., Beach, K., & Nesbitt, L. (1998). Platelet serotonin transporter in depressed children and adolescents: 3H-paroxetine platelet binding before and after sertraline. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 777-784.
26. Sallee, F., & Smirnov, A. (2003). Atomoxetine: Novel therapy for ADHD and potential therapeutic implications. Primary Psychiatry, 10, 41-48.
27. Sallee, F., Vrindavanam, N., Deas-Nesmith, D., Carson, S., & Sethuraman, G. (1997). Pulse intravenous clomipramine for depressed adolescents: Double-blind controlled trial. American Journal of Psychiatry, 154, 668-673.
28. Spencer, T., Heiligenstein, J.H., Biederman, J., Faries, D.F., Kratochvil, C.J., Conners, C.K., et al. (2002). Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with ADHD. Journal of Clinical Psychiatry, 63, 1140-1147.
29. Treatment for Adolescents with Depression Study Team. (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. Journal of the American Medical Association, 292, 807-820.
30. Varley, C.K., & Smith, C.J. (2003). Anxiety disorders in the child and teen. Pediatric Clinics of North America, 50, 1107-1138.
31. Velosa, J.F., & Riddle, M.A. (2000). Pharmacologic treatment of anxiety disorders in children and adolescents. Child & Adolescent Psychiatric Clinics of North America, 9, 119-133.
32. Wernicke, J.F., Adler, L., Spender, T., West, S.A., Allen, A.H., Heiligenstein, J., et al. (2004). Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with ADHD: A prospective, placebo controlled assessment. Journal of Clinical Psychopharmacology, 24, 30-35.
33. Whittington, C.J., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., & Boddington, E. (2004). Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet, 363, 1341-1345.
34. Wilens, T.E., Faraone, S.V., & Biederman, J. (2003). Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics, 111, 179-185.
35. Williams, T.P., & Miller, B.D. (2003). Pharmacologic management of anxiety disorders in children and adolescents. Current Opinions in Pediatrics, 15, 483-490.